Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (July 2017)
19 slides from Blis Technologies's shareholder meeting presentation, Jul 28, 2017
Slide 1: CEO Presentation
CEO Presentation Brian Watson 28/07/2017
Slide 2: Important Notice
IMPORTANT NOTICE This presentation is given on behalf of Blis Technologies Limited. Information in this presentation: • Should be read in conjunction with Blis Technologies’ Annual Reports, Interim Reports and market releases on NZX; • May contain projections or forward-looking statements about Blis
Slide 3: CEO and functional areas
CEO Finance & Business Science / R & D Marketing Manufacturing Quality logistics Development Professor John Tagg
Slide 4: Presentation topics
Presentation topics 1. Market opportunity 2. Positioned for sustainable profitable growth 3. Future focus
Slide 5: 1. The market opportunity
1. The market opportunity • Market drivers • Addressable market • The Blis Value proposition
Slide 6: Market Drivers
Market Drivers The Human Microbiome – An Dietary supplements growth – explosion of science and interest Probiotics stand out performance Oral Human Microbiome – The community of bacteria that live on and in the Human body Gut The microbiome plays a major role in health and Urogenital disease and rep
Slide 7: The Human Microbiome
The Human Microbiome Oral • An explosion of science and interest • Probiotics represent an accepted approach influencing the microbiome and delivering health benefits • Gut – Crowded market with limited Gastro- opportunity for differentiation intestinal • Beyond gut – Opportunity to innovate and Ski
Slide 8: Probiotic supplements growth
Probiotic supplements growth 2016 Global • Dietary supplements $53 b Retail Value • Probiotic supplements $4.3 b US$ • Global growth 2016 9% Growth in • Forecast 38% growth 2016-2021 (+ probiotic $1.6 b) supplements • Probiotics forecast to be the fastest growing category • Increased consumer owners
Slide 9: Addressable market
Addressable market Oral • Ear, Nose and Throat • Oral (Tooth, Gum, Halitosis) Gut • Skin Urogenital Skin
Slide 10: The BLIS Value Proposition
The BLIS Value Proposition We are leaders in the manufacture of advanced probiotic strains that go beyond the gut We combine innovation with a strong evidence base and the highest quality controls to develop probiotic solutions for specific health targets BLIS® – Advanced Probiotic Defence
Slide 11: 2. Positioned for sustainable profitable growth
2. Positioned for sustainable profitable growth • Highlights from FY17 • Financial • Non financial foundations • Scientific leadership
Slide 12: Highlights: Year ended March 2017
Highlights: Year ended 31 March 2017 • Positive EBITDA - $585k • $845 k improvement on last year • Net deficit of $24 k • 16% revenue growth • Revenue growth in all export markets • NZ retail sales growth 10% FY2018 - May 29 2017 Guidance “During this financial year, the company will continue to inv
Slide 13: FY17 Regional sales performance
FY17 Regional sales performance (excluding Nutritional contract manufacture) $1.68 M + 14% $2.32 M $1.32 M North America + 9% + 76% Europe Asia Stratum Nutrition Bluestone Pharma Japan – Tradepia China - NZPR $0.88 M Total global revenue: +20% FY15 $2.63 M FY16 $5.66 M Australasia FY17 $6.55 M NZ –
Slide 14: Highlights: Non financial
Highlights: Non financial • Appointment of key staff • Chief Marketing Officer, Chief Technical Officer, Science Manager, Business Development Manager • New product launches • HoneyBlisTM • ToothGuardTM and ToothGuardTM Junior • BLIS EliteProTM (targeting athletes) • Establishment of an independent
Slide 15: Commercially focused scientific leadership
50 years of Commercially focused research by Emeritus Professor John scientific leadership Tagg 2 commercialized strains and 30+ completed pipeline of new clinical studies strain potential Scientific Leadership 40+ Patents Science advisory group
Slide 16: 3. Our future focus
3. Our future focus FY18 and beyond Growing the business Investing in the pipeline FY17 Building the business
Slide 17: Marketing support & sales growth
Marketing support & sales growth • Portfolio revision and launch activity • Focus consistency of value proposition • Broader and deeper channel presence Pharmacy counter Building our multichannel presence display Glen Innes, Auckland • Pharmacy • Dental • Health stores, allied health professionals U
Slide 18: Pipeline investment
Pipeline investment • New strain development • Skin probiotic under development, targeting launch FY2019 • Prioritisation and development of other strains from our library • Novel product formats • Ongoing clinical trials providing expanded evidence • Market access/ Regulatory expansion • Managing I
Slide 19: Thank You
Thank You want! fee